

Chapter 194

Varicella and Herpes Zoster

Kenneth E. Schmader & Michael N. Oxman

REFERENCES

1. Choo PW et al: The epidemiology of varicella and its complications. *J Infect Dis* 172:706, 1995
2. Seward J et al: Epidemiology of varicella. In: *Varicella-Zoster Virus. Virology and Clinical Management*, edited by Arvin AM, Gershon AA. Cambridge: Cambridge University Press; 2000, p. 187
3. Kilgore PE et al: Varicella in Americans from NHANES III: Implications for control through routine immunization. *J Med Virol* 70:S111, 2003
4. Nguyen HQ, Jumaan AO, Seward JF: Decline in mortality due to varicella after implementation of varicella vaccination in the United States. *N Engl J Med* 352:450, 2005
5. Meyer PA et al: Varicella mortality: Trends before licensure in the United States, 1970–1994. *J Infect Dis* 182:383, 2000
6. Luman ET et al: Uptake of varicella vaccination among young children in the United States: A success story in eliminating racial and ethnic disparities. *Pediatrics* 117:999, 2006
7. Seward JF et al: Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. *JAMA* 287:606, 2002
8. Jumaan AO et al: Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. *J Infect Dis* 191:2002, 2005
9. Davis MM, Patel MS, Gebremariam A: Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics* 114:786, 2004
10. Guris D et al: Changing varicella epidemiology in active surveillance sites—United States, 1995–2005. *J Infect Dis* 197:S71, 2008
11. White CJ et al: Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. *Pediatrics* 87:604, 1991
12. Sawyer MH et al: Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. *J Infect Dis* 166:885, 1992
13. Donahue JG et al: The incidence of herpes zoster. *Arch Intern Med* 155:1605, 1995
14. Hope-Simpson RE: The nature of herpes zoster: A long-term study and a new hypothesis. *Proc R Soc Med* 58:9, 1965
15. Mullooly JP et al: Incidence of herpes zoster, 1997–2002. *Epidemiol Infect* 133:245, 2005
16. Opstelten W et al: Herpes zoster and postherpetic neuralgia: Incidence and risk indicators using a general practice research database. *Family Practice* 19:471–475, 2002
17. Oxman MN et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med* 352:2271, 2005
18. Ragozzino MW et al: Population-based study of herpes zoster and its sequelae. *Medicine (Baltimore)* 6:310, 1982
19. Schmader KE, George LK, Hamilton JD: Racial differences in the occurrence of herpes zoster. *J Infect Dis* 171:701, 1995
20. Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? *Lancet Infect Dis* 4:26, 2004
21. Yawn BP et al: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. *Mayo Clin Proc* 82:1341, 2007
22. Schmader KE, Gnann JW, Watson CPN: The epidemiological, clinical, and pathological rationale for the zoster vaccine. *J Infect Dis* 197:S207, 2008
23. Harpaz R, Ortega-Sanchez IR, Seward JF: Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Report*. 57(RR-5):1–30, 2008
24. Thomas SL, Wheeler JG, Hall AJ: Case-control study of the effect of mechanical trauma on the risk of herpes zoster. *BMJ* 328:439, 2004
25. Haanpaa M, Nurmikko T, Hurme M: Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. *Scand J Infect Dis* 34:112, 2002

26. Brisson M et al: Exposure to varicella boosts immunity to herpes zoster: Implications for mass vaccination against chickenpox. *Vaccine* **20**:2500, 2002
27. Kalman CM, Laskin OL: Herpes zoster and zosteriform herpes simplex infections in immunocompetent adults. *Am J Med* **81**:775, 1986
28. Lopez AS et al: Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. *J Infect Dis* **197**:646, 2008
29. Yih WK et al: The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. *BMC Public Health* **5**:68, 2005
30. Marin M et al: Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* **56**:1–40, 2007
31. Pellett P, Roizman B: The family herpesviridae: A brief introduction. In: *Fields Virology*, Vol. 2, 5th edition, D Knipe, C Howley, eds. Philadelphia, Lippincott Williams and Wilkins; 2007, p. 2479
32. Cohen JI, Straus SE, Arvin AM: Varicella-zoster virus replication, pathogenesis and management. In: *Fields Virology*, Vol. 2, 5th edition, edited by D Knipe, P Howley. Philadelphia, Lippincott Williams & Wilkins; 2007, p. 2744
33. Oxman MN: Zoster vaccine: Current status and future prospects. *Clin Infect Dis* **51**:197, 2010
34. Ku CC et al: Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. *J Virol* **76**:11425, 2002
35. Ku CC et al: Varicella-zoster virus pathogenesis and immunobiology: New concepts emerging from investigations with the SCIDhu mouse model. *J Virol* **79**:2651, 2005
36. Arvin AM: Investigations of the pathogenesis of varicella zoster virus infection in the SCIDhu mouse model. *Herpes* **13**:75, 2006
37. Arvin AM: Cell-mediated immunity to varicella-zoster virus. *J Infect Dis* **166**:S35, 1992
38. Arvin AM: Humoral and cellular immunity to varicella-zoster virus: An overview. *J Infect Dis* **197**:S58, 2008
39. Oxman MN: Clinical manifestations of herpes zoster, In: *Varicella-Zoster Virus: Virology and Clinical Management*, edited by AM Arvin, AA Gershon. Cambridge, UK, Cambridge University Press; 2000, p. 246
40. Levin MJ et al: Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. *J Infect Dis* **188**:1336–1344, 2003
41. Krause PR, Klinman DM: Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children. *Nat Med* **6**:451, 2000
42. Head H, Campbell AW: The pathology of herpes zoster and its bearing on sensory localization. *Brain* **23**:353, 1900
43. Watson CPN et al: Postherpetic neuralgia: Further post-mortem studies of cases with and without pain. *Pain* **44**:101, 1991
44. Satyaprakash AK et al: Viremia in acute herpes zoster. *J Infect Dis* **200**:26, 2009
45. Kost RG, Straus SE: Postherpetic neuralgia: Pathogenesis, treatment, and prevention. *N Engl J Med* **335**:32, 1996
46. Rowbotham M et al: Spectrum of pain mechanisms contributing to PHN. In: *Herpes Zoster and Postherpetic Neuralgia*, 2nd edition, edited by CPN Watson, AA Gershon. Amsterdam, Elsevier; 2001, p. 167
47. Johnson C et al: A long-term prospective study of varicella vaccine in healthy children. *Pediatrics* **100**:761, 1997
48. Lewis GW: Zoster sine herpete. *Br Med J* **2**:418, 1958
49. Liesegang TJ: Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. *Ophthalmology* **115**:S3, 2008
50. Katz J et al: Acute pain in herpes zoster and its impact on health-related quality of life. *Clin Infect Dis* **39**:342, 2004
51. Schmader KE et al: The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. *Clin J Pain* **23**:490, 2007
52. Boivin G et al: Diagnosis of viral infections. In: *Clinical Virology*, 3rd edition, edited by DD Richman, RJ Whitley, FG Hayden. Washington, DC, ASM Press, 2009, p. 265
53. Harbecke R et al: A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. *J Med Virol* **81**:1310, 2009
54. Steinberg SP, Gershon AA: Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. *J Clin Microbiol* **29**:1527, 1991

55. Aebi C et al: Bacterial complications of primary varicella in children. *Clin Infect Dis* 23:698, 1996
56. Kiska DL et al: Invasive group A streptococcal infections in North Carolina: Epidemiology, clinical features and genetic and serotype analysis of causative organisms. *J Infect Dis* 176:992, 1997
57. Patel RA, Binns HJ, Shulman ST: Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. *J Pediatr* 144:68, 2004
58. Danovaro-Holliday MC et al: High rate of varicella complications among Mexican-born adults in Alabama. *Clin Infect Dis* 39:1633, 2004
59. Wallace MR et al: Treatment of adult varicella with oral acyclovir: A randomized, placebo-controlled study. *Ann Intern Med* 117:358, 1992
60. Enders G et al: Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 cases. *Lancet* 343:1548, 1994
61. Centers for Disease Control: Reye syndrome—United States, 1984. *MMWR Morb Mortal Wkly Rep* 34:13, 1985
62. Liu GT, Urion DK: Pre-eruptive varicella encephalitis and cerebellar ataxia. *Pediatr Neurol* 8:69, 1992
63. Holland GN: Standard diagnostic criteria for the acute retinal necrosis syndrome. *Am J Ophthalmol* 117:663, 1994
64. Muthiah MN et al: Acute retinal necrosis: A national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. *Br J Ophthalmol* 91:1452, 2007
65. Gilden DH et al: Neurologic complications of the reactivation of varicella-zoster virus. *N Engl J Med* 342:635, 2000
66. Desmond RA et al: Clinical applications for change-point analysis of herpes zoster pain. *J Pain Symptom Manage* 23:510, 2002
67. Jung BF et al: Risk factors for postherpetic neuralgia in patients with herpes zoster. *Neurology* 62:1545, 2004
68. Hope-Simpson RE: Postherpetic neuralgia. *J R Coll Gen Pract* 25:571, 1975
69. Choo PW et al: Risk factors for postherpetic neuralgia. *Arch Intern Med* 157:1217, 1997
70. Dworkin RH, Schmader KE: The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: *Herpes Zoster and Postherpetic Neuralgia*, 2nd edition, edited by CPN Watson, AA Gershon. Amsterdam, Elsevier, 2001, p. 51
71. Dunkle LM et al: A controlled trial of acyclovir for chickenpox in normal children. *N Engl J Med* 325:1539, 1991
72. Klassen TP et al: Acyclovir for treating varicella in otherwise healthy children and adolescents. *Cochrane Database Syst Rev* (4):CD002980, 2005
73. Varicella-Zoster Infections in: Report of the Committee on Infectious Diseases. American Academy of Pediatrics (Red Book): 714, 2009
74. Balfour HH et al: Acyclovir treatment of varicella in otherwise healthy adolescents. *J Pediatr* 120:627, 1992
75. Haake DA et al: Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: Retrospective controlled study and review. *Rev Infect Dis* 12:788, 1990
76. Nyerges G et al: Acyclovir prevents dissemination of varicella in immunocompromised children. *J Infect Dis* 157:309, 1988
77. Dworkin RH et al: Recommendations for the management of herpes zoster. *Clin Infect Dis* 44:S1, 2007
78. Tying S et al: Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia: A randomized double-blind, placebo-controlled trial. *Ann Intern Med* 123:89, 1995
79. Gnann JW Jr, Whitley RJ: Herpes zoster. *N Engl J Med* 347:340, 2002
80. Beutner KR et al: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. *Antimicrob Agents Chemother* 39:1546, 1995
81. Tying SK et al: Antiviral therapy for herpes zoster: Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. *Arch Fam Med* 9:863, 2000
82. Degreef H: Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. *Int J Antimicrob Agents* 4:241, 1994
83. Cobo LM et al: Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. *Ophthalmology* 93:763, 1986
84. Colin J et al: Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. *Ophthalmology* 107:1507, 2000

85. Tyring S et al: Famciclovir for ophthalmic zoster: A randomized, acyclovir controlled study. *Br J Ophthalmol* **85**:576, 2001
86. Balfour HH Jr et al: Acyclovir halts progression of herpes zoster in immunocompromised patients. *N Engl J Med* **308**:1448, 1983
87. Whitley RJ et al: Disseminated herpes zoster in the immunocompromised host: A comparative trial of acyclovir and vidarabine. *J Infect Dis* **165**:450, 1992
88. Gnann JW et al: Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial. *Antimicrob Agents Chemother* **42**:1139, 1998
89. Tyring S et al: A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. *Cancer Invest* **19**:13, 2001
90. Wood MJ et al: A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. *N Engl J Med* **330**:896, 1994
91. Whitley RJ et al: Acyclovir with and without prednisone for the treatment of herpes zoster: A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. *Ann Intern Med* **125**:376, 1996
92. He L et al: Corticosteroids for preventing postherpetic neuralgia. *Cochrane Database Syst Rev* (1):CD005582, 2008
93. Dworkin RH et al: Oxycodone or gabapentin for acute pain in herpes zoster: A randomized, placebo-controlled trial. *Pain* **142**:209, 2009
94. Berry JD, Petersen KL: A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. *Neurology* **65**:444, 2005
95. van Wijck AJ et al: The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: A randomised controlled trial. *Lancet* **367**:219, 2006
96. Dworkin RH et al: Pharmacologic management of neuropathic pain: Evidence-based recommendations. *Pain* **132**:237, 2007
97. Dubinsky RM et al: Practice Parameter: Treatment of postherpetic neuralgia. *Neurology* **63**:959, 2004
98. Attal N et al: EFNS guidelines on pharmacological treatment of neuropathic pain. *Eur J Neurol* **13**:1153, 2006
99. Backonja M et al: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomised, double-blind study. *Lancet Neurology* **7**:1106, 2008
100. Hempenstall K et al: Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. *Plos Med* **2**:e164, 2005
101. Moulin DE et al: Canadian Pain Society: Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society. *Pain Res Manage* **12**:13, 2007
102. Galer BS et al: Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. *Pain* **80**:533, 1999
103. Rowbotham M et al: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. *JAMA* **280**:1837, 1998
104. Rice ASC, Maton S, Postherpetic Neuralgia Study Group: Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. *Pain* **94**:215, 2001
105. Dworkin RH et al: Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. *Neurology* **60**:1274, 2003
106. Moore RA et al: Pregabalin for acute and chronic pain in adults. *Cochrane Database Syst Rev* (3):CD007076, 2009
107. Sabatowski R et al: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. *Pain* **109**:26, 2004
108. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* (4):CD005454, 2007
109. Watson CPN et al: Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. *Neurology* **51**:1166, 1998
110. Watson CPN et al: Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. *Neurology* **50**:1837, 1998
111. Raja SN et al: Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. *Neurology* **59**:1015, 2002
112. Gilron I et al: Morphine, gabapentin, or their combination for neuropathic pain. *New Engl J Med* **352**:1324, 2005

113. Gilron I et al: Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomized controlled crossover trial. *Lancet* **374**:1252, 2009
114. Marin M et al: Importance of catch-up vaccination: Experience from a varicella outbreak, Maine, 2002–2003. *Pediatrics* **115**:900, 2005
115. Asano Y et al: Experience and reason: Twenty-year follow-up of protective immunity of the Oka live varicella vaccine. *Pediatrics* **94**:524, 1994
116. Galil K et al: Outbreak of varicella at a day-care center despite vaccination. *N Engl J Med* **347**:1909, 2002
117. Vazquez M et al: Effectiveness over time of varicella vaccine. *JAMA* **291**:851, 2004
118. Seward JF et al: Contagiousness of varicella in vaccinated cases: A household contact study. *JAMA* **292**:704, 2004
119. Chaves SS et al: Loss of vaccine-induced immunity to varicella over time. *N Engl J Med* **356**:1121, 2007
120. Chaves SS et al: Varicella disease in vaccinated persons: Clinical and epidemiologic characteristics, 1997–2005. *J Infect Dis* **197**:S127, 2008
121. Chaves SS et al: Safety of varicella vaccine after licensure in the United States: Experience from reports to the vaccine adverse event reporting system, 1995–2005. *J Infect Dis* **197**:S170, 2008
122. Watson B et al: Postexposure effectiveness of varicella vaccine. *Pediatrics* **105**:84, 2000
123. A New Product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. *MMWR* **55**(08):209-210, 2006. <http://www.cdc.gov/nip/vaccine/varicella/default.htm>
124. Asano Y et al: Postexposure prophylaxis of varicella in family contact by oral acyclovir. *Pediatrics* **92**:219, 1993
125. Garner JS: Guideline for isolation precautions in hospitals. The Hospital Infection Control Advisory Committee. *Infect Control Hosp Epidemiol* **17**:53, 1996
126. Bolyard EA et al: Guidelin for Infection Control in Health Care Personnel. *AJIC* **26**:289, 1998
127. Oxman MN: Immunization to reduce the frequency and severity of herpes zoster and its complications. *Neurology* **45**:841, 1995
128. Levin MJ et al: Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. *J Infect Dis* **178**:S109, 1998
129. Simberkoff MS et al: Safety of zoster vaccine in the shingles prevention study: A randomized trial. *Ann Intern Med* **152**:545, 2010
130. Kroger AT et al: Advisory Committee on Immunization Practice (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* **55**(RR-15);1-48, 2006

